What are the major challenges for CAR T-cell therapies in Europe during the COVID-19 pandemic?

During the Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Lymphoma Hub spoke to Sara Ghorashian, University College London, London, UK. We asked, What are the major challenges for CAR T-cell therapies in Europe during the COVID-19 pandemic?

The COVID-19 pandemic has had an impact on the logistics of the already complex delivery of chimeric antigen receptor (CAR) T-cell therapies, by delaying both clinical studies and CAR T-cell accreditation for many centers. Ghorashian provides an overview of the challenges faced and dimensions to consider for the future, including vaccination, complications, and disease context.